STREAMEX CORP. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
STREAMEX CORP. (STEX) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-14.
Discontinued › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2024-04-16
- STREAMEX CORP. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-12-31 was $0.00.
- STREAMEX CORP. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- STREAMEX CORP. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-06-30 was $502.00K.
- STREAMEX CORP. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- STREAMEX CORP. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $502.00K, a 37.25% decline from fiscal 2021.
- STREAMEX CORP. right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $800.00K, a 39900.00% increase from fiscal 2020.
- STREAMEX CORP. right-of-use asset obtained in exchange for operating lease liability for fiscal 2020 was $2.00K, a 99.66% decline from fiscal 2019.
- STREAMEX CORP. right-of-use asset obtained in exchange for operating lease liability for fiscal 2019 was $588.00K.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month as first filed |
|---|---|---|---|---|---|---|
| 2023-06-30 | $0.00 10-Q · filed 2023-08-14 | |||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-16 | $0.00 derived: sum of 2 quarters · filed 2024-04-16 | $502.00K derived: sum of 3 quarters · filed 2024-04-16 | $502.00K 10-K · filed 2024-04-16 | ||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $502.00K derived: sum of 2 quarters · filed 2023-11-14 | $502.00K 10-Q · filed 2023-11-14 | $502.00K derived: sum of 4 quarters · filed 2023-11-14 | ||
| 2022-06-30 | $502.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $502.00K 10-Q · filed 2023-08-14 | $502.00K derived: sum of 3 quarters · filed 2023-08-14 | $1.08M derived: sum of 4 quarters · filed 2023-08-14 | ||
| 2022-03-31 | $0.00 10-Q · filed 2022-05-16 | $0.00 derived: sum of 2 quarters · filed 2023-03-31 | $582.00K derived: sum of 3 quarters · filed 2023-03-31 | $582.00K derived: sum of 4 quarters · filed 2023-03-31 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $582.00K derived: sum of 2 quarters · filed 2023-03-31 | $582.00K derived: sum of 3 quarters · filed 2023-03-31 | $800.00K 10-K · filed 2023-03-31 | ||
| 2021-09-30 | $582.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $582.00K derived: sum of 2 quarters · filed 2022-11-14 | $800.00K 10-Q · filed 2022-11-14 | $802.00K derived: sum of 4 quarters · filed 2022-11-14 | ||
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $218.00K 10-Q · filed 2022-08-15 | $220.00K derived: sum of 3 quarters · filed 2022-08-15 | $220.00K derived: sum of 4 quarters · filed 2022-08-15 | ||
| 2021-03-31 | $218.00K 10-Q · filed 2022-05-16 | $220.00K derived: sum of 2 quarters · filed 2022-05-16 | $220.00K derived: sum of 3 quarters · filed 2022-05-16 | $220.00K derived: sum of 4 quarters · filed 2022-05-16 | ||
| 2020-12-31 | $2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $2.00K derived: sum of 2 quarters · filed 2022-03-31 | $2.00K derived: sum of 3 quarters · filed 2022-03-31 | $2.00K 10-K · filed 2022-03-31 | ||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $0.00 derived: sum of 2 quarters · filed 2021-11-15 | $0.00 10-Q · filed 2021-11-15 | $76.76K derived: sum of 4 quarters · filed 2021-11-15 | ||
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $0.00 10-Q · filed 2021-08-11 | $76.76K derived: sum of 3 quarters · filed 2021-08-11 | $81.72K derived: sum of 4 quarters · filed 2021-08-11 | ||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-17 | $76.76K derived: sum of 2 quarters · filed 2021-05-17 | $81.72K derived: sum of 3 quarters · filed 2021-05-17 | |||
| 2019-12-31 | $76.76K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-15 | $81.72K derived: sum of 2 quarters · filed 2021-03-15 | $588.00K 10-K · filed 2021-03-15 | $511.24K 10-K · filed 2020-03-13 | ||
| 2019-09-30 | $4.96K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $511.24K 10-Q · filed 2020-11-05 | ||||
| 2019-06-30 | $506.28K 10-Q · filed 2020-08-06 | |||||
| 2019-01-01 | $419.00K 10-K · filed 2020-03-13 | |||||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | $0.00 derived: sum of 2 quarters · filed 2020-03-13 | $0.00 10-K · filed 2020-03-13 | |||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-23 | $0.00 10-Q · filed 2019-10-23 | ||||
| 2018-06-30 | $0.00 10-Q · filed 2019-07-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nexalin Technology, Inc. (NXL) | United States | $0.094B | |
| Neuraxis, INC (NRXS) | United States | $0.097B | |
| electroCore, Inc. (ECOR) | United States | $0.102B | |
| Vivani Medical, Inc. (VANI) | United States | $0.111B | |
| Outset Medical, Inc. (OM) | United States | $0.059B | -1.09 |
| PRECISION OPTICS CORPORATION, INC. (POCI) | United States | $0.052B | |
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |
| QT IMAGING HOLDINGS, INC. (QTI) | United States | $0.037B | |
| IRIDEX CORP (IRIX) | United States | $0.011B | |
| ENDRA Life Sciences Inc. (NDRA) | United States | $0.009B |